CA3001661C - HIGH-DOSE STATINS FOR AGE-RELATED MACULAR DEGENERATION - Google Patents
HIGH-DOSE STATINS FOR AGE-RELATED MACULAR DEGENERATIONInfo
- Publication number
- CA3001661C CA3001661C CA3001661A CA3001661A CA3001661C CA 3001661 C CA3001661 C CA 3001661C CA 3001661 A CA3001661 A CA 3001661A CA 3001661 A CA3001661 A CA 3001661A CA 3001661 C CA3001661 C CA 3001661C
- Authority
- CA
- Canada
- Prior art keywords
- patient
- amd
- dose
- dose statin
- statin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562241522P | 2015-10-14 | 2015-10-14 | |
| US62/241,522 | 2015-10-14 | ||
| PCT/US2016/056987 WO2017066529A1 (en) | 2015-10-14 | 2016-10-14 | High-dose statins for age-related macular degeneration |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA3001661A1 CA3001661A1 (en) | 2017-04-20 |
| CA3001661C true CA3001661C (en) | 2025-05-06 |
Family
ID=58517927
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3001661A Active CA3001661C (en) | 2015-10-14 | 2016-10-14 | HIGH-DOSE STATINS FOR AGE-RELATED MACULAR DEGENERATION |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11331295B2 (https=) |
| EP (1) | EP3362063B1 (https=) |
| JP (3) | JP7037186B2 (https=) |
| AU (1) | AU2016338540B2 (https=) |
| CA (1) | CA3001661C (https=) |
| DK (1) | DK3362063T3 (https=) |
| ES (1) | ES2941347T3 (https=) |
| FI (1) | FI3362063T3 (https=) |
| IL (1) | IL258604B2 (https=) |
| MX (1) | MX391944B (https=) |
| PH (1) | PH12018500745B1 (https=) |
| WO (1) | WO2017066529A1 (https=) |
| ZA (1) | ZA201803097B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11789024B2 (en) | 2017-05-09 | 2023-10-17 | Massachusetts Eye And Ear Infirmary | Biomarkers for age-related macular degeneration |
| EP3654941A1 (en) * | 2017-07-17 | 2020-05-27 | Keith Roizman | Topical delivery of therapeutic agents comprising cell-penetrating peptides for use for the treatment of age-related macular degeneration and other eye diseases |
| WO2019079515A1 (en) * | 2017-10-17 | 2019-04-25 | Apeliotus Technologies, Inc. | FUNCTIONAL BIOMARKERS FOR STATIN-BASED TREATMENT IN AGE-RELATED MACULAR DEGENERATION (AMD) |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030065020A1 (en) * | 2001-07-13 | 2003-04-03 | Catharine Gale | Treatment of macular degeneration |
| CA2478317A1 (en) | 2002-03-04 | 2003-09-18 | Medimmune, Inc. | Methods of preventing or treating disorders by administering an integrin .alpha.v.beta.3 antagonist in combination with an hmg-coa reductase inhibitor or a bisphosphonate |
| WO2005083430A1 (en) | 2004-02-25 | 2005-09-09 | Massachusetts Eye & Ear Infirmary | Biomarkers for age-related macular degeneration (amd) |
| US7919094B2 (en) | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| WO2006083533A2 (en) * | 2005-01-14 | 2006-08-10 | The Regents Of The University Of California | Compositions and methods for inhibiting drusen formation and for diagnosing or treating drusen-related disorders |
| US20100034749A1 (en) | 2006-07-10 | 2010-02-11 | Medigene Ag | Use of a Cationic Collodal Preparation for the Diagnosis and Treatment of Ocular Diseases |
| JP2008268506A (ja) * | 2007-04-19 | 2008-11-06 | Fuji Xerox Co Ltd | 現像装置、像保持体ユニットおよび画像形成装置 |
| WO2009023411A1 (en) | 2007-08-09 | 2009-02-19 | Bausch & Lomb Incorporated | Compositions and methods for treating or controlling anterior- and posterior-segment ophthalmic diseases |
| US20120156202A1 (en) | 2010-11-05 | 2012-06-21 | Shantha Totada R | Age related macular degeneration treatment |
| EP3041479B1 (en) | 2013-09-06 | 2023-04-26 | Vanda Pharmaceuticals Inc. | Treatment of cyr61- and vegf-mediated conditions |
| WO2016009430A1 (en) | 2014-07-14 | 2016-01-21 | Yeda Research And Development Co. Ltd | Reduction of aging-induced type i interferon signaling at the brain's choroid plexus or within the cns for treatment of disease or injury of the cns |
| MX383117B (es) | 2014-07-31 | 2025-03-13 | Anji Pharmaceuticals Inc | Péptidos miméticos de la apoe y mayor potencia para depurar el colesterol en plasma. |
-
2016
- 2016-10-14 CA CA3001661A patent/CA3001661C/en active Active
- 2016-10-14 AU AU2016338540A patent/AU2016338540B2/en active Active
- 2016-10-14 FI FIEP16856248.6T patent/FI3362063T3/fi active
- 2016-10-14 JP JP2018519309A patent/JP7037186B2/ja active Active
- 2016-10-14 WO PCT/US2016/056987 patent/WO2017066529A1/en not_active Ceased
- 2016-10-14 US US15/768,367 patent/US11331295B2/en active Active
- 2016-10-14 DK DK16856248.6T patent/DK3362063T3/da active
- 2016-10-14 EP EP16856248.6A patent/EP3362063B1/en active Active
- 2016-10-14 MX MX2018004636A patent/MX391944B/es unknown
- 2016-10-14 PH PH1/2018/500745A patent/PH12018500745B1/en unknown
- 2016-10-14 IL IL258604A patent/IL258604B2/en unknown
- 2016-10-14 ES ES16856248T patent/ES2941347T3/es active Active
-
2018
- 2018-05-11 ZA ZA2018/03097A patent/ZA201803097B/en unknown
-
2020
- 2020-12-01 US US17/108,065 patent/US11744817B2/en active Active
-
2021
- 2021-09-10 JP JP2021147620A patent/JP7754480B2/ja active Active
-
2023
- 2023-10-13 JP JP2023177353A patent/JP2024016045A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| ES2941347T3 (es) | 2023-05-22 |
| FI3362063T3 (fi) | 2023-04-06 |
| JP2022003042A (ja) | 2022-01-11 |
| EP3362063A4 (en) | 2019-06-19 |
| JP7754480B2 (ja) | 2025-10-15 |
| IL258604A (en) | 2018-06-28 |
| US20210077457A1 (en) | 2021-03-18 |
| US20190209522A1 (en) | 2019-07-11 |
| IL258604B2 (en) | 2024-09-01 |
| MX2018004636A (es) | 2019-06-20 |
| IL258604B1 (en) | 2024-05-01 |
| DK3362063T3 (da) | 2023-04-03 |
| MX391944B (es) | 2025-03-21 |
| EP3362063A1 (en) | 2018-08-22 |
| US11331295B2 (en) | 2022-05-17 |
| EP3362063B1 (en) | 2023-01-11 |
| NZ742203A (en) | 2025-06-27 |
| US11744817B2 (en) | 2023-09-05 |
| PH12018500745B1 (en) | 2023-03-15 |
| JP2024016045A (ja) | 2024-02-06 |
| CA3001661A1 (en) | 2017-04-20 |
| ZA201803097B (en) | 2022-12-21 |
| JP7037186B2 (ja) | 2022-03-16 |
| JP2018530586A (ja) | 2018-10-18 |
| PH12018500745A1 (en) | 2018-10-15 |
| WO2017066529A1 (en) | 2017-04-20 |
| AU2016338540B2 (en) | 2022-04-28 |
| AU2016338540A1 (en) | 2018-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024016045A (ja) | 加齢黄斑変性のための高用量スタチン | |
| Holz et al. | Geographic atrophy: clinical features and potential therapeutic approaches | |
| RU2444356C2 (ru) | Полиненасыщенные жирные кислоты для лечения деменции и состояний, связанных с преддеменцией | |
| Zhang et al. | Apigenin protects mouse retina against oxidative damage by regulating the Nrf2 pathway and autophagy | |
| US20100087474A1 (en) | Materials and methods for enhanced degradation of mutant proteins associated with human disease | |
| JP2014515408A (ja) | 行動及び精神障害の治療のためのシロ−イノシトール | |
| US20170368184A1 (en) | Self-emulsifying composition of omega-3 fatty acid | |
| CN103998034A (zh) | ω脂肪酸用于治疗疾病的用途 | |
| JP2016539098A (ja) | 網膜の血管障害を治療又は予防する方法 | |
| EP2994197B1 (en) | Pharmaceutical combination of an nsaid and atropine | |
| Shome et al. | Stages, pathogenesis, clinical management and advancements in therapies of age-related macular degeneration | |
| Liu et al. | Bone marrow mesenchymal stem cells enhance autophagy and help protect cells under hypoxic and retinal detachment conditions | |
| WO2011097577A2 (en) | Compositions and methods for treating or preventing retinal degeneration | |
| Chen et al. | Vitamin K1 alleviates retinal inflammation following acute ocular hypertension by modulating microglial ferroptosis | |
| RU2489146C1 (ru) | Способ лечения "сухой" формы возрастной макулярной дегенерации | |
| Jain | Neuroprotection in Alzheimer disease | |
| US20200360331A1 (en) | COMPOSITIONS COMPRISING 15-HEPE AND/OR 15-HETrE AND METHODS OF TREATING OR PREVENTING CARDIOMETABOLIC DISEASE, METABOLIC SYNDROME, AND/OR RELATED DISEASES | |
| US12076304B2 (en) | Compositions comprising 15-HEPE and methods of treating or preventing hematologic disorders, and/or related diseases | |
| Olchawa | The effect of oxidative stress on phagocytic activity of retinal pigment epithelium cells in vitro | |
| WO2023004044A2 (en) | Compositions and methods for treating neurodegenerative diseases by inhibiting fsh | |
| CN101287370A (zh) | 用于增强与人类疾病相关的突变蛋白质的降解的物质与方法 | |
| HK40080196A (en) | Biomolecule for treatment of corneal pathologies | |
| Rathore et al. | Review on age related macular degeneration | |
| EP3648794A1 (en) | Use of macroazapyridinophanes metal complexes in the treatment of diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20211012 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - SMALL Year of fee payment: 8 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241002 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241002 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241002 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-4-D10-D22-D143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRE-GRANT Effective date: 20250304 |
|
| Q17 | Modified document published |
Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q17-Q103 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DOCUMENT PUBLISHED Effective date: 20250501 |
|
| F11 | Ip right granted following substantive examination |
Free format text: ST27 STATUS EVENT CODE: A-4-4-F10-F11-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: GRANT BY ISSUANCE Effective date: 20250506 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250526 |